Pharmaceutical compounds
    2.
    发明授权
    Pharmaceutical compounds 失效
    药物化合物

    公开(公告)号:US5891877A

    公开(公告)日:1999-04-06

    申请号:US693172

    申请日:1996-09-25

    摘要: Diketopiperazines of the formula ##STR1## where one or both of R.sub.1 and R.sub.2, which are different, are chosen from X and a phenyl group substituted by X, C(O)X, OC(O)CH.sub.2 X, OCH.sub.2 CH.sub.2 X, CH.sub.2 X, CONH(CH.sub.2).sub.n X, O(CH.sub.2).sub.n CH(OH)(CH.sub.2).sub.n X ##STR2## and, where appropriate, the other of R.sub.1 and R.sub.2 is a phenyl group optionally substituted by one or more groups selected from halogen, nitro, methoxy, NHC(O)R.sub.12, CO.sub.2 H, O(CH.sub.2).sub.n N(R.sub.12 R.sub.13), C.sub.1 -C.sub.4 alkyl and (CH.sub.2).sub.n C(O)OR.sub.12 ; X is a five- or six-membered heterocyclic ring selected from the group consisting of pyridyl, imidazolyl, furyl, pyrrolyl, pyrrolidinyl, thienyl, piperazinyl, piperidinyl, morpholinyl, quinolyl, isoquinotyl and indolyl, the heteroatom(s) of the said heterocyclic ring, when nitrogen, being optionally substituted by hydrogen, methyl, oxygen, tertiary-butyloxycarbonyl, or SO.sub.2 Me, the heterocyclic ring being optionally substituted by halogen �hydrogen!, methyl, MeS, phenyl, O(CH.sub.2).sub.n N(R.sub.12 R.sub.13) or optionally containing one or more carbonyl groups and being optionally fused to a benzene ring; Y is O or S; R.sub.12 and R.sub.13, which may be the same or different, are hydrogen or C.sub.1 -C.sub.6 alkyl; and n is 0 or an integer having the value 1, 2, 3 or 4; a pharmaceutically acceptable salts or esters having activity as inhibitors of plasminogen activator inhibitor.

    摘要翻译: PCT No.PCT / GB95 / 00302 Sec。 371日期1996年9月25日 102(e)日期1996年9月25日PCT提交1995年2月14日PCT公布。 出版物WO95 / 21832 日期为1995年8月17日,由X,C(O)X,OC(O)CH 2 X,OCH 2 CH 2 X,CH 2 X,CONH(CH 2)n X,O( CH 2)n CH(OH)(CH 2)n X ,并且在适当的情况下,R 1和R 2中的另一个是任选被一个或多个选自卤素,硝基,甲氧基,NHC(O)R 12,CO 2 H ,O(CH 2)n N(R 12 R 13),C 1 -C 4烷基和(CH 2)n C(O)OR 12; X是选自吡啶基,咪唑基,呋喃基,吡咯基,吡咯烷基,噻吩基,哌嗪基,哌啶基,吗啉基,喹啉基,异喹啉基和吲哚基的五元或六元杂环,所述杂环的杂原子 环,任选地被氢,甲基,氧,叔丁氧基羰基或SO 2 Me取代,杂环任选被卤素[氢],甲基,MeS,苯基,O(CH 2)n N(R 12 R 13)或任选地被 含有一个或多个羰基并任选地与苯环稠合; Y为O或S; R 12和R 13可以相同或不同,是氢或C 1 -C 6烷基; 并且n为0或具有值1,2,3或4的整数; 具有作为纤溶酶原激活物抑制剂抑制剂活性的药学上可接受的盐或酯。

    Pharmaceutical diketopiperazine compounds
    4.
    发明授权
    Pharmaceutical diketopiperazine compounds 失效
    药物二酮哌嗪化合物

    公开(公告)号:US5750530A

    公开(公告)日:1998-05-12

    申请号:US750020

    申请日:1996-12-17

    摘要: A diketopiperazine of formula (I): ##STR1## wherein each of R.sub.7 and R.sub.8 which may be the same or different; is hydrogen or a nitro group; Y is ##STR2## --O-- or --S--, wherein each of R.sub.9 and R.sub.10 which may be the same or different, is hydrogen or a nitro group; n is 0, 1 or 2; m is an integer of 1 to 6; each R.sub.6, which may be the same or different, is a C.sub.1 -C.sub.6 alkyl group; and X is selected from (i) a phenyl group of the following formula ##STR3## and the salts and esters thereof; have activity as inhibitors of plasminogen activator inhibitor.

    摘要翻译: PCT No.PCT / GB95 / 01180 Sec。 371日期1996年12月17日第 102(e)日期1996年12月17日PCT提交1995年5月24日PCT公布。 公开号WO95 / 32190 日期:1995年11月30日A式(I)的二酮哌嗪:其中R 7和R 8各自可以相同或不同; 是氢或硝基; Y是-O-或-S-,其中可以相同或不同的R 9和R 10各自是氢或硝基; n为0,1或2; m为1〜6的整数。 每个R 6可以相同或不同,是C 1 -C 6烷基; 并且X选自(i)下式的苯基作为纤溶酶原激活物抑制剂的抑制剂的活性。